Propeller Health, a company that trains its digital eye on respiratory medicine, first partnered with GSK in 2015. Now, that collaboration is being expanded -- enabling both companies to prepare for, and undertake, commercial activities using the Propeller clip-on sensor and software platform for use with GSK’s ELLIPTA Inhaler.
 
Ongoing research and development efforts will continue, with evidence collected from the Propeller package used in conjunction with GSK’s respiratory medicines for asthma and COPD.
 
The expanded collaboration follows the late-2016 CE marking and US FDA 510(k) class II clearance of the Propeller sensor and software program for the ELLIPTA Inhaler. The clip-on sensor for the ELLIPTA Inhaler automatically records medication use, which the Propeller platform analyzes and presents to patients and physicians through its interface, providing an in-depth look at adherence.
 
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the US,” said David Van Sickle, CEO and co-founder of Propeller, in a statement. “Companion digital experiences simplify and personalize the management of chronic respiratory disease, and help ensure individuals and their physicians realize the benefits of inhaled medicines.”
 
Eric Dube, senior Vice president and head of Global Respiratory Franchise GSK, said in a statement that digital innovations such as sensor technologies “will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition. We are excited to expand our collaboration with Propeller as a further step in our journey towards achieving connected health systems for people with asthma and COPD.”
 
GSK has been in the respiratory space for more than 45 years, developing new medicines, approaches and insights which have supported the management of asthma and chronic obstructive pulmonary disease.
 
The ELLIPTA inhaler is a platform inhaler device that is being used by GSK in the development of a range of medicines across its clinical development portfolio for respiratory diseases.